NATALIE VERENES: Open Payments
NPI 1477068864 · COLUMBIA, SC. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,249 in 152 payments from 11 companies in 2025. Trend: 2023 $2,134 · 2024 $2,138 · 2025 $2,249
Food & beverage: $2,138Education: $111
| Company | Payments | Amount |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 50 | $477 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 20 | $349 |
| Neurocrine BioSciences, Inc. | 28 | $349 |
| Janssen Pharmaceuticals, Inc | 12 | $325 |
| Alkermes, Inc. | 17 | $310 |
| E.R. Squibb & Sons, L.L.C. | 12 | $212 |
| Otsuka America Pharmaceutical, Inc. | 9 | $151 |
| Axsome Therapeutics, Inc. | 1 | $21 |
| ABBVIE INC. | 1 | $19 |
| Vanda Pharmaceuticals Inc. | 1 | $19 |
Products named: CAPLYTA, INGREZZA, INVEGA SUSTENNA, ARISTADA, COBENFY, AUSTEDO XR, UZEDY, ABILIFY MAINTENA.
Industry payments across SC — which companies pay providers there.
